The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Open accessAbstract
Slowing Brain Disease with Gene Therapy: X-linked adrenoleukodystrophy (ALD), the hereditary brain demyelinating disorder that was featured in the movie “ Lorenzo's Oil ,” is typically treated by transplantation of bone marrow from matched donors. This treatment slows progression of the disease by introducing cells that differentiate into myelin-producing cells. Cartier et al. (p. 818 ; see Perspective by Naldini ) tested an alternative gene therapy–based approach in two young patients without matched donors. A lentiviral vector was used to introduce a wild-type copy of the ALD gene into the patients' hematopoietic stem cells ex vivo. The modified cells were then infused back into the patients. Expression of the transferred gene was still detectable in the patients' blood cells 2 years later, and both patients showed neurological improvement and a delay in disease progression comparable to that seen with bone marrow transplants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Expansions of cells with a common integration site were observed in a gene therapy trial using lentiviral vectors for adrenoleukodystrophy [51].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [51]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Gene therapy is a cutting-edge approach that has shown potential in various genetic disorders, including X-ALD.”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lentiviral vector-based gene transfer into CD34 + HSCs has subsequently been applied in the treatment of several genetic diseases, including β-thalassemia [67], X-linked adrenoleukodystrophy [51], metachromatic leukodystrophy [68, 69], and Wiskott-Aldrich Syndrome [70].”
From Clinical use of lentiviral vectors (2018) · cites this paper as [51]
The cited source says what the claim attributes to it.
In the citing paper
“Early-stage treatment of childhood cerebral ALD with hematopoietic stem cell transplantation and, more recently, gene therapy can arrest disease progression if performed in the window of opportunity when the MRI is abnormal but neurological symptoms are not yet apparent [7,38,43,44,45,46,47,48,49,50].”
From Structure and Function of the ABCD1 Variant Database: 20 Years, 940 Pathogenic Variants, and 3400 Cases of Adrenoleukodystrophy (2022) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“A lentiviral vector has been used to introduce a wild-type copy of the ABCD1 gene into the patients’ hematopoietic stem cells ex vivo. Subsequently, the genetically modified cells have been reintroduced into the patients (48).”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“The positive results of HSC transplantation into cALD patients [24,356] indicated a role for brain microglia because microglia were thought to originate in bone marrow at that time [357].”
From Revisiting the Pathogenesis of X-Linked Adrenoleukodystrophy (2025) · cites this paper as [356]
In the citing paper
“In ALD, phagocytes derived from autologous bone marrow transplants likely elicit their beneficial effects by replacing mutant microglia, as they stall terminal neuro-inflammation and demyelination 42.”
From Efficient derivation of microglia-like cells from human pluripotent stem cells (2016) · cites this paper as [42]
In the citing paper
“Allogenic hematopoietic stem cell transplantation [145,146] and autologous stem cell-based gene therapy [147] can arrest the inflammatory demyelinating process with a typical delay of 12–18 months, which has been attributed to the slow replacement of microglia with bone marrow-derived phagocytes [147,148].”
From Peroxisomes in brain development and function (2016) · cites this paper as [147]
In the citing paper
“This is strongly supported by the fact that both allogeneic hematopoietic stem cell (HSC) transplantation and autologous HSC gene therapy are very effective in arresting and even reversing neuroinflammatory cerebral ALD, provided that the procedure is performed at an early stage [101,102].”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [102]
In the citing paper
“In 2009, autologous HSCT was demonstrated to be successful to halt cerebral demyelination in two boys with no compatible donors who received their own genetically corrected stem cells [ 82 ].”
From Peroxisomal ABC Transporters: An Update (2021) · cites this paper as [82]
In the citing paper
“These promising results suggest that such a therapeutic strategy may be as effective as allogeneic HSCT.”
From Peroxisomal ABC Transporters: An Update (2021) · cites this paper as [82]
In the citing paper
“the CD34+ PBMCs (lymphoid and myeloid progenitors) transduced with normal ABCD1 can efficiently correct the clinical phenotype of the X-ALD patients [ 82 ]”
From Peroxisomal ABC Transporters: An Update (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Self-citationGene therapy of human severe combined immunodeficiency (SCID)-X1 disease.
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,703
Self-citationProjection of an Immunological Self Shadow Within the Thymus by the Aire Protein
Anderson, M. S., Venanzi, E. S., Klein, L., Chen, Z.-B., Berzins, S., Turley, S., von Boehmer, H., Bronson, R., Dierich, A., Benoist, C., et al. (2002) · Science · doi:10.1126/science.1075958 · Cited by 2,582
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
van Gent, R. N., Siem, D., van Middelkoop, M., van Os, A. G., Bierma‐Zeinstra, S., & Koes, B. W. (2007) · British Journal of Sports Medicine · doi:10.1136/bjsm.2006.033548 · Cited by 1,505
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M., Glorioso, J., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,444
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Loes D. J., et al.., Am. J. Neuroradiol. 15, 1761 (1994).7847225
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Dasouki, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802896-4.00007-9 · Cited by 11
Transplantation as disease modifying therapy in adults with inherited metabolic disorders
Sirrs, S. M., Hannah‐Shmouni, F., Nantel, S. H., Neuberger, J., & Yoshida, E. M. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0141-z · Cited by 10
“Although short-term outcomes of ex vivo gene therapy of clinical trials in various IMDs, such as metachromatic leukodystrophy (Sessa et al 2016) and X-ALD (Cartier et al 2009), have been reported, there were no adults included in these studies to allow comparison of the adult and pediatric outcomes.”
BackgroundRanea‐Robles, P., Galino, J., Espinosa, L., Schlüter, A., Ruíz, M., Calingasan, N. Y., Villarroya, F., Naudí, A., Pamplona, R., Ferrer, I., et al. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12747 · Cited by 10
Hematopoietic Stem Cell: Regulation and Nutritional Intervention
Sun, S., Han, Y., Lei, Y., Yu, Y., Dong, Y., & Chen, J. (2023) · Nutrients · doi:10.3390/nu15112605 · Cited by 10
“…al. initiated the lentiviral-mediated gene therapy of hematopoietic stem cells in X-linked adrenoleukodystrophy (ALD) patients and found that this therapy led to successful allogeneic hematopoietic cell transplantation, indicating that this approach offered therapeutic benefits to ALD patients [60].”
BackgroundGene Therapy for Primary Immunodeficiencies
Fischer, A., Hacein‐Bey‐Abina, S., & Cavazzana, M. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.11.007 · Cited by 10
Self-citationStable Long-Term Blood Formation by Stem Cells in Murine Steady-State Hematopoiesis
Zavidij, O., Ball, C. R., Herbst, F., Oppel, F., Fessler, S., Schmidt, M., Kalle, C. V., & Glimm, H. (2012) · Stem Cells · doi:10.1002/stem.1151 · Cited by 10
Self-citationVector Production in an Academic Environment: A Tool to Assess Production Costs
Boeke, A., Doumas, P., Reeves, L., McClurg, K., Bischof, D., Sego, L. M., Auberry, A., Tatikonda, M. V., & Cornetta, K. G. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.213 · Cited by 10
“Recent successes in gene therapy clinical trials for genetic diseases such as adenosine deaminase deficiency, adrenoleukodystrophy, Leber congenital amaurosis, and hemophilia have energized the field (Bainbridge et al., 2008; Maguire et al., 2008; Aiuti et al., 2009; Cartier et al., 2009; Nathwani et al., 2011).”
BackgroundA Graph Based Framework to Model Virus Integration Sites
Fronza, R., Vasciaveo, A., Benso, A., & Schmidt, M. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.10.006 · Cited by 10
“Viral vector integration is a process exploited in gene therapy (GT) to correct defective cells of an individual and to drive the health status from the pathological condition to a normal one [1 – 6].”
BackgroundSelf-citationGriffin, D. O., & Goff, S. P. (2016) · Retrovirology · doi:10.1186/s12977-016-0246-0 · Cited by 10
“Gene therapy is currently in progress with success in a number of patients with a range of genetic disorders such as immunodeficiency due to adenosine deaminase deficiency [3], Wiskott–Aldrich syndrome [4], metachromic leukodystrophy [5], X-linked severe combined immunodeficiency [6], β-thalassemia [7], sickle cell an…”
BackgroundMashima, R., Tanaka, M., Sakai, E., Nakajima, H., Kumagai, T., Kosuga, M., & Okuyama, T. (2016) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2016.02.007 · Cited by 10
Tani, K. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2030-2 · Cited by 11
“Thus, lentiviralmediated gene therapy of HSCs provided clinical benefits in ALD [56].”
BackgroundInfluentialSakurai, K., Ohashi, T., Shimozawa, N., Seo, J.-H., Okuyama, T., & Ida, H. (2018) · Brain and Development · doi:10.1016/j.braindev.2018.07.007 · Cited by 10
Suryawanshi, G. W., Khamaikawin, W., Wen, J., Shimizu, S., Arokium, H., Xie, Y., Wang, E., Kim, S., Choi, H., Zhang, C., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay9206 · Cited by 10
“These IS sequence collisions are a common problem for modern high-throughput sequencing (34, 45), likely occurring due to sample cross-contamination or demultiplexing errors (e.”
BackgroundStem Cell Applications in Lysosomal Storage Disorders: Progress and Ongoing Challenges
Köse, S., Aerts‐Kaya, F., Uçkan, D., & Korkusuz, P. (2021) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_639 · Cited by 10
Özgür-Günes, Y., Chedik, M., Le Stunff, C., Fovet, C.-M., & Bougnères, P. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.293 · Cited by 10
Haematopoietic stem cell gene therapy in inborn errors of metabolism
Chiesa, R., & Bernardo, M. E. (2022) · British Journal of Haematology · doi:10.1111/bjh.18179 · Cited by 7
Dong, L.-W., Xiao, J., Liu, S., Deng, G., Liao, Y.-C., Chu, B., Zhao, X., Song, B., & Luo, J. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2260-4 · Cited by 10
“Indeed, ABCD1 deficiency is reported to compromise the integrity of blood-brain barrier (Aubourg, 2015; Cartier et al., 2009; Musolino et al., 2015).”
BackgroundGene therapy for Down syndrome
Fillat, C., & Altafaj, X. (2012) · Progress in brain research · doi:10.1016/b978-0-444-54299-1.00012-1 · Cited by 11
Yokoi, T., Kobayashi, H., Shimada, Y., Eto, Y., Ishige, N., Kitagawa, T., Otsu, M., Nakauchi, H., Ida, H., & Ohashi, T. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1566 · Cited by 10
Verhoeyen, E., Relouzat, F., Cambot, M., Costa, C., Négre, D., Legrand, F., Joubert, C., Grand, R. L., Cosset, F., Leboulch, P., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.020 · Cited by 13
“…has resulted in proof-of-principle of efficacy in clinical trials for several inherited diseases that include X-linked severe combined immunodeficiency (X-SCID) syndrome (Cavazzana-Calvo et al., 2000), adrenoleukodystrophy (Car- tier et al., 2009), and b-thalassemia (Cavazzana-Calvo et al., 2010).”
BackgroundSelf-citationCounsell, J. R., Karda, R., Diaz, J. F. A., Carey, L., Wiktorowicz, T., Buckley, S. M. K., Ameri, S., Ng, J., Baruteau, J., Almeida, F., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.07.006 · Cited by 10
Genetic strategies for the treatment of sickle cell anaemia
Mansilla‐Soto, J., Rivière, I., & Sadelain, M. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08773.x · Cited by 12
Correction of Fanconi Anemia Group C Hematopoietic Stem Cells Following Intrafemoral Gene Transfer
Habi, O., Girard, J., Bourdages, V., Delisle, M., & Carreau, M. (2010) · Anemia · doi:10.1155/2010/947816 · Cited by 10
Dix ans de thérapie génique Réflexions
Cavazzana, M., Hacein‐Bey‐Abina, S., & Fischer, A. (2010) · médecine/sciences · doi:10.1051/medsci/2010262115 · Cited by 10
Self-citationKanai, Y., Onishi, M., Yoshida, Y., Kotaki, T., Minami, S., Nouda, R., Yamasaki, M., Enoki, Y., & Kobayashi, T. (2023) · Journal of Virology · doi:10.1128/jvi.00492-23 · Cited by 9
Non‐viral Gene Therapy for Melanoma Using Lysenin from Eisenia Foetida
Ren, M., Yang, L., He, L., Wang, J., Zhao, W., Yang, C. C., Yang, S., Cheng, H., Huang, M., & Gou, M. (2024) · Advanced Science · doi:10.1002/advs.202306076 · Cited by 8
Hematopoietic stem cell gene therapy to halt neurodegeneration
Biffi, A. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00440 · Cited by 10
“First in human testing started in 2006 in France with a pioneering Phase I/II clinical trial (NCT01896102) that enrolled four boys in whom functional human ALDP expression and disease stabilization were observed after myeloablative conditioning and transplantation of engineered autologous HSCs [45].”
BackgroundGarcía‐Cazorla, À., Sevin, C., Ribeiro‐Constante, J., Yazbeck, E., Rosewich, H., Jimenez, S., Chiang, G. C.-Y., Rapalino, O., Caruso, P. A., Balentine, D., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103265 · Cited by 9
Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects
Jaballah, S. A., Ali, L. M., Jehad, M. A., Akhlaq, S., Rizvi, T. A., & Mustafa, F. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169473 · Cited by 10
The discovery and development of RNA-based therapies for treatment of HIV-1 infection
Chen, M. J., Gatignol, A., & Scarborough, R. J. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2117296 · Cited by 9
Gene Therapy for Cardiomyocyte Renewal: Cell Cycle, a Potential Therapeutic Target
Son, Y., & Zhu, W. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00625-y · Cited by 9
Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders
Buffa, V., Vargas, J. R. A., Galy, A. H. M., Spinozzi, S., & Rocca, C. J. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.997142 · Cited by 10
“Although the mechanism of rescue is unclear, allogeneic and autologous lentiviral-based HSCT have shown to be effective in the treatment of X-ALD when performed at an early stage of disease (Cartier et al., 2009; Cartier and Aubourg, 2010; Cartier et al., 2012; Eichler et al., 2017).”
BackgroundEx vivo factor VIII ‐modified proliferating human hepatocytes therapy for haemophilia A
Zhang, K., Wu, N., Cen, J., Li, J., Wang, Z., Xia, Q., & Hui, L. (2023) · Cell Proliferation · doi:10.1111/cpr.13467 · Cited by 9
Fortin, P., Lepetit‐Coiffé, M., Genevois, C., Debeissat, C., Quesson, B., MOONEN, C. T. W., Konsman, J. P., & Couillaud, F. (2015) · Oncotarget · doi:10.18632/oncotarget.4288 · Cited by 9
“Moreover, genetic modification in vitro of bone marrow cells before engraftment has been also tested in a clinical trial [25, 26].”
BackgroundDelivery of Genome Editing Reagents to Hematopoietic Stem/Progenitor Cells
Hoban, M. D., Romero, Z. G., Cost, G. J., Mendel, M. C., Holmes, M. C., & Kohn, D. B. (2016) · Current Protocols in Stem Cell Biology · doi:10.1002/9780470151808.sc05b04s36 · Cited by 9
Adeno associated viral-mediated intraosseous labeling of bone marrow derived cells for CNS tracking
Selenica, M. B., Reid, P., Pena, G., Alvarez, J., Hunt, J. B., Nash, K. R., Morgan, D., Gordon, M. N., & Lee, D. C. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.01.008 · Cited by 9
“Hematopoietic stem cells have been used as a gene delivery vehicle in severe combined immunodeficiency (SCID) and adenoleukodystrophy (ALD) and have been successfully translated into clinical trials [24, 25].”
BackgroundHuang, S., Bruce, T. F., Ding, H., Wei, Y., & Marcus, R. K. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03232-8 · Cited by 10
The impact of clonal diversity and mosaicism on haematopoietic function in Fanconi anaemia
Hughes, A. D., & Kurre, P. (2021) · British Journal of Haematology · doi:10.1111/bjh.17653 · Cited by 10
Using Pulmozyme DNase Treatment in Lentiviral Vector Production
Shaw, A., Bischof, D., Jasti, A. C., Ernstberger, A. G., Hawkins, T., & Cornetta, K. G. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.204 · Cited by 9
“L entiviral vectors have shown promise as a new therapeutic tool for patients with life-threatening disorders (Levine et al. , 2006; Cartier et al. , 2009; Cavazzana-Calvo et al. , 2010; DiGiusto et al. , 2010; Kalos et al. , 2011).”
Wang, J., Yu, Y., YAN, Z., Hu, Z., Li, L., Jiang, L., Jiang, X., & Qian, Q. (2013) · Oncology Reports · doi:10.3892/or.2013.2511 · Cited by 9
Multi-Institutional Assessments of Transplantation for Metabolic Disorders
Orchard, P. J., Boelens, J. J., & Raymond, G. V. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.10.026 · Cited by 9
Cantone, I. (2017) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2017.19 · Cited by 9
“Importantly, rescue of disease symptoms has also been observed in human and mouse upon gene therapy of X-linked adrenoleukodystrophy([18]) and Hunter syndrome([19,20]), two recessive X-linked diseases that also affect heterozygous females([16,21]).”
BackgroundPuig-Saus, C., Parisi, G., García-Díaz, Á., Krystofinski, P. E., Sandoval, S., Zhang, R., Champhekar, A. S., McCabe, J. G., Cheung-Lau, G. C., Truong, N. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0963 · Cited by 9
“However, clinical trials using SIN-lentiviral vectors with the closely related MND promoter derived from the MPSV murine gamma-retrovirus (42) to drive the expression of the ABCD1 gene have shown safety and lack of clonal expansion of the modified cells (43, 44).”
Weber, T., & Köhler, W. (2010) · Der Nervenarzt · doi:10.1007/s00115-010-2948-1 · Cited by 9
Worgall, S., & Crystal, R. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398358-9.00034-3 · Cited by 12
Enfermedades de la corteza suprarrenal
Raux-Demay, M. C. (2010) · EMC - Pediatría · doi:10.1016/s1245-1789(10)70167-0 · Cited by 9
An Emerging Era of Clinical Benefit From Gene Therapy
Malech, H. L., & Ochs, H. D. (2015) · JAMA · doi:10.1001/jama.2015.2055 · Cited by 10
Weber, F. D., Weinhofer, I., Einwich, A., Forss-Petter, S., Muneer, Z., Maier, H., Weber, W. H. A., & Berger, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103742 · Cited by 8
“CALD has a typical onset during childhood (35–40”
InfluentialPetrillo, C., Calabria, A., Piras, F., Capotondo, A., Spinozzi, G., Cuccovillo, I., Benedicenti, F., Naldini, L., Montini, E., Biffi, A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.016 · Cited by 8
Integrating Viral and Nonviral Vectors for Cystic Fibrosis Gene Therapy in the Airways
Cooney, A. L., McCray, P. B., & Sinn, P. L. (2015) · InTech eBooks · doi:10.5772/60977 · Cited by 9
A lentiviral vector pseudotype suitable for vaccine development
Lopes, L. M., Dewannieux, M., Takeuchi, Y., & Collins, M. K. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1553 · Cited by 9
Application of Viruses for Gene Therapy and Vaccine Development
Lundstrom, K. H. (2022) · Advances in environmental microbiology · doi:10.1007/978-3-030-85395-2_9 · Cited by 8
Inderbitzin, A., Loosli, T., Kouyos, R. D., & Metzner, K. J. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.06.003 · Cited by 9
In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model
Gopalappa, R., Lee, M., Kim, G., Jung, E. S., Lee, H., Hwang, H.-Y., Lee, J. G., Kim, S. J., Yoo, H. J., Sung, Y. H., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.027 · Cited by 8
Gene therapy strategies for RAG1 deficiency: Challenges and breakthroughs
Gilioli, G., Lankester, A. C., de Kivit, S., Staal, F. J. T., & de Bruin, L. M. O. (2024) · Immunology Letters · doi:10.1016/j.imlet.2024.106931 · Cited by 8
Strategies for Retrovirus-Based Correction of Severe, Combined Immunodeficiency (SCID)
Fischer, A., Hacein‐Bey‐Abina, S., & Cavazzana, M. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00002-8 · Cited by 8
Self-citationLentiviral vectors for cutaneous RNA managing
Primo, M. N., Bak, R. O., & Mikkelsen, J. G. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01436.x · Cited by 8
Current translational and clinical practices in hematopoietic cell and gene therapy
DiGiusto, D. L., & Kiem, H. (2012) · Cytotherapy · doi:10.3109/14653249.2012.694420 · Cited by 9
Gene therapy as a vaccine for HIV-1
Berkhout, B., & Sanders, R. W. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707177 · Cited by 8
“Gene therapy is explored as a novel means for curing chronic genetic diseases or chronic infections, with a number of recent success stories [47,48].”
BackgroundWang, X., Liu, P., Liu, H., Yang, W., Liu, Z., Zhuo, Z., & Gao, Y. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.65 · Cited by 9
Zhang, W., Chen, H., Zheng, X., Wang, D., Ji, H., Xia, H., & Mao, Q. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.08.003 · Cited by 8
“Model T” Cells: A Time-Tested Vehicle for Gene Therapy
Kerkar, S. P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00304 · Cited by 8
“The ability to stably introduce functional genes into hematopoietic stem cells or differentiated cells ex vivo provides hope for the thousands of patients diagnosed with a wide range of devastating genetic diseases, highlighted by recent successes in childhood cerebral adrenoleukodystrophy (75) and hemophilia B (76).”
BackgroundNovel Immunotherapies for the Treatment of Melanoma
Gato, M., Arasanz, H., Blanco‐Luquin, I., Glaría, E., Arteta-Sanchez, V., Kochan, G. T., & Escors, D. (2016) · Immunotherapy · doi:10.2217/imt-2015-0024 · Cited by 10
Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy
Cowan, M. J., Dvorak, C. C., & Long-Boyle, J. R. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.003 · Cited by 8
Vojnits, K., Nakanishi, M., Porras, D. P., Kim, Y., Feng, Z., Golubeva, D., & Bhatia, M. (2022) · Molecules · doi:10.3390/molecules27082434 · Cited by 10
Parameswaran, J., Goicoechea, L., Planas‐Serra, L., Pastor, A., Ruíz, M., Calingasan, N. Y., Guilera, C., Aso, E., Boada, J., Pamplona, R., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02451-2 · Cited by 9
Vector Systems for Prenatal Gene Therapy: Principles of Retrovirus Vector Design and Production
Howe, S. J., & Chandrashekran, A. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-873-3_5 · Cited by 8
Surface Modification of Retroviral Vectors for Gene Therapy
Metzner, C., & Dangerfiel, J. (2011) · InTech eBooks · doi:10.5772/20568 · Cited by 8
Is genetic rescue of cystinosis an achievable treatment goal?
Cherqui, S. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft270 · Cited by 8
“We are working with human CTNS complementary DNA (cDNA) in this animal study and using a vector backbone currently in application in clinical trials [37] to establish the preclinical proof of concept for a human trial.”
Gene therapy: too much splice can spoil the dish
Trono, D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63066 · Cited by 8
Auditory agnosia as a clinical symptom of childhood adrenoleukodystrophy
Furushima, W., Kaga, M., Nakamura, M. M., Gunji, A., & Inagaki, M. (2014) · Brain and Development · doi:10.1016/j.braindev.2014.10.011 · Cited by 8
Rouanet, S., Warrick, E., Gache, Y., Scarzello, S., Avril, M., Bernerd, F., & Magnaldo, T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020019 · Cited by 8
“Using such an improved lentivirus generation, Cartier and colleagues reported significant clinical benefits in two patients suffering from Adrenoleukodystrophy (ALD, a severe demyelinating disease) [62].”
BackgroundTargeting Myeloid Cells to the Brain Using Non-Myeloablative Conditioning
Böttcher, C., Fernández‐Klett, F., Gladow, N., Rolfes, S., & Priller, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080260 · Cited by 8
Gene therapy: Progress in childhood disease
Ginn, S. L., & Alexander, I. E. (2011) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2011.02204.x · Cited by 8
Strategies for More Rapid Translation of Cellular Therapies for Children: A US Perspective
López-Sánchez, R. C., Silberstein, L. E., Lindblad, R., Welniak, L. A., Mondoro, T. H., & Wagner, J. E. (2013) · PEDIATRICS · doi:10.1542/peds.2012-3383 · Cited by 9
Transporteurs ABC peroxysomaux et adrénoleucodystrophie liée au chromosome X
Geillon, F., Trompier, D., Gondcaille, C., Lizard, G., & Savary, S. (2012) · médecine/sciences · doi:10.1051/medsci/20122812019 · Cited by 9
Disorders in the Initial Steps in Steroidogenesis
Miller, W. L., & Gucev, Z. S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00011-9 · Cited by 7
Challenges and advances in translating gene therapy for hearing disorders
Büning, H., Schambach, A., Morgan, M. A., Rossi, A., Wichova, H., Staecker, H., Warnecke, A., & Lenarz, T. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1707077 · Cited by 8
“Application of third-generation lentiviral SIN vectors was shown to be safe in several clinical studies [50,51].”
BackgroundGene therapy for disorders of the central nervous system
Aubourg, P. R. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-59565-2.00056-3 · Cited by 8
Self-citationGonçalves, C., Gross, F., Guégan, P., Cheradame, H., & Midou, P. (2014) · Biotechnology Journal · doi:10.1002/biot.201400324 · Cited by 8
Zheng, Q., Zhang, X., Yang, H., Xie, J., Xie, Y., Chen, J., Yu, C., & Chen, Z. (2019) · Viruses · doi:10.3390/v11100920 · Cited by 8
“For example, in phase I/II clinical trials, genetic modification was achieved in only 9–14% of blood cells after transplant of a self-inactivating lentiviral vector [21].”
BackgroundMission possible: Gene therapy for inherited metabolic diseases
Baruteau, J., Keshavan, N., & Venditti, C. P. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12708 · Cited by 8
Weighing the Risks of Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy
Dunbar, C. E. (2024) · New England Journal of Medicine · doi:10.1056/nejme2409399 · Cited by 8
RNA splicing factor Rbm25 underlies heterogeneous preleukemic clonal expansion in mice
Bramlett, C. S., Eerdeng, J., Du, J., Lee, Y., Garcia, I., Vergel-Rodriguez, M., Condie, P., Nogalska, A., & Lu, R. (2023) · Blood · doi:10.1182/blood.2023019620 · Cited by 8
Carvalho, S., Santos, J. I., Moreira, L., Gonçalves, M., David, H., Matos, L., Encarnação, M., Alves, S., & Coutinho, M. F. (2023) · Biomedicines · doi:10.3390/biomedicines11041234 · Cited by 7
Salafutdinov, I. I., Gatina, D. Z., Markelova, M., Garanina, E. E., Malanin, S. Y., Gazizov, I. M., Izmailov, A., Rizvanov, A. A., Islamov, R. R., Palotás, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11072020 · Cited by 7
“The natural limits of CNS regeneration pose major problems for the treatment of neurological disorders of various aetiologies [7].”
InfluentialClonal tracking in cancer and metastasis
Aalam, S. M. M., Nguyen, L. V., Ritting, M. L., & Kannan, N. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10149-4 · Cited by 8
Hematopoietic stem cell therapy and ex vivo gene therapy for X-linked adrenoleukodystrophy
Eichler, F., & Kuehl, J.-S. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90242-7.00018-3 · Cited by 7
Supporting Regenerative Medicine by Integrative Dimensionality Reduction
Mulas, F., Žagar, L., Zupan, B., & Bellazzi, R. (2012) · Methods of Information in Medicine · doi:10.3414/me11-02-0045 · Cited by 7
Anticancer Gene Transfer for Cancer Gene Therapy
Pazarentzos, E., & Mazarakis, N. D. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4471-6458-6_13 · Cited by 7
Gene therapy: Myth or reality?
Fischer, A. (2016) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2016.04.011 · Cited by 10
Self-citationRetroviral Transduction of Murine and Human Hematopoietic Progenitors and Stem Cells
Ciuculescu, M. F., Brendel, C., Harris, C. E., & Williams, D. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1133-2_20 · Cited by 7
Cherqui, S. (2023) · médecine/sciences · doi:10.1051/medsci/2023025 · Cited by 7
Targeted Lentiviral Vectors: Current Applications and Future Potential
Goyvaerts, C., Liechtenstein, T., Bricogne, C., Escors, D., & Breckpot, K. (2013) · InTech eBooks · doi:10.5772/52770 · Cited by 8
Myeloid cell-based therapies in neurological disorders: How far have we come?
Böttcher, C., & Priller, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.003 · Cited by 7
Nondividing Cells: A Safer Bet for Integrating Vectors?
Brady, T., & Bushman, F. D. (2011) · Molecular Therapy · doi:10.1038/mt.2011.40 · Cited by 7
Potic, A., Rovelli, A., Uziel, G., Kozic, D. B., Mladenovic, J., & Milic-Rasic, V. M. (2010) · Journal of Child Neurology · doi:10.1177/0883073810375117 · Cited by 7
Stripecke, R. (2014) · Biomedicines · doi:10.3390/biomedicines2030229 · Cited by 7
“LV have been recently shown to be safe in several gene therapy clinical trials for gene replacement in hematopoieitic stem cells for diseases such as adrenoleukodistrophy [13], Wiskott Aldrich syndrome [14] and metachromatic leukodystrophy [15].”
BackgroundPossible Applications for Replicating Hiv-1 Vectors
Das, A. T., Jeeninga, R. E., & Berkhout, B. (2010) · HIV Therapy · doi:10.2217/hiv.10.20 · Cited by 7
Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible
Cappa (2011) · PubMed · doi:10.3275/7570 · Cited by 14
Metadata
- Authors
- Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., Mahlaoui, N., Kiermer, V., Mittelstaedt, D., Bellesme, C., Lahlou, N., Lefrère, F., Blanche, S., Audit, M., Payen, E., Leboulch, P., l’Homme, B., Bougnères, P., Von Kalle, C., Fischer, A., Cavazzana-Calvo, M., & Aubourg, P.
- Affiliations
- Inserm (FR)
- Department of Biotherapy, Hôpital Necker-Enfants Malades, 75743 Paris, France.
- German Cancer Research Center (DE)
- 117 Southwest 72nd Place, Gainesville, FL 32608, USA.
- Hôpital Necker-Enfants Malades (FR)
- Nature Publishing Group, New York, NY 10013–1917, USA.
- 13687 Quinton Road, San Diego, CA 92129, USA.
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Saint-Vincent-de-Paul (FR)
- GenoSafe (FR)
- Brigham and Women's Hospital (US)
- Department of Pediatric Endocrinology and Neurology, Hôpital Saint-Vincent de Paul, Assistance Publique–Hôpitaux de Paris, 82 Avenue Denfert-Rochereau, 75674 Paris, France.
- National Center for Tumor Diseases and German Cancer Research Center (Deutsches Krebsforschungszentrum), 69120 Heidelberg, Germany.
- Corresponding author
- Cartier, Nathalie
- Aubourg, Patrick
- ORCID
- Venue
- Science
- Published
- 2009-11-06
- Volume
- 326
- Issue
- 5954
- Pages
- 818-823
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2141570423
- Cited by
- 1,508
- References
- 40
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 54 · 2023: 50 · 2022: 62 · 2021: 56 · 2020: 71 · 2019: 61 · 2018: 76 · 2017: 96 · 2016: 98 · 2015: 107 · 2014: 130 · 2013: 137 · 2012: 139
- FWCI
- 84.34
- Type
- journal article
- Language
- en
- Open access
- green
- cea.hal.science
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (SPP 1230)
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Association Européenne contre les Leucodystrophies
- Assistance publique-Hôpitaux de Paris
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- X-linked adrenoleukodystrophy, hematopoietic stem cell gene therapy, lentiviral vectors, ABCD1 gene, myeloablative conditioning, demyelination
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily D, Member 1, Adrenoleukodystrophy, Animals, Brain, Cell Differentiation, Child, Fatty Acids, Female, Genetic Vectors, Hematopoiesis, Hematopoietic Stem Cells, Humans, Leukocytes, Mononuclear, Male, Transduction, Genetic, Transplantation, Autologous, Genetic Therapy, HIV-1, Gene Expression, Virus Integration, Microglia, Hematopoietic Stem Cell Transplantation, Disease Progression, ATP-Binding Cassette Transporters, Cell Lineage, Transplantation Conditioning, Myeloablative Agonists, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
